(Q46538510)

23 December 2017

title

A PEACE-ful solution to COPD exacerbations? (English)

1 reference

23 December 2017

author name string

Paul Albert

series ordinal

1

1 reference

23 December 2017

Peter Calverley

series ordinal

2

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

23 December 2017

published in

The Lancet

1 reference

23 December 2017

volume

371

1 reference

23 December 2017

issue

9629

1 reference

23 December 2017

page(s)

1975-1976

1 reference

23 December 2017

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960845-4

7 January 2021

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960845-4

7 January 2021

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960845-4

7 January 2021

What have we learned from large drug treatment trials in COPD?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960845-4

7 January 2021

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960845-4

7 January 2021

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960845-4

7 January 2021

Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960845-4

7 January 2021

Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960845-4

7 January 2021

Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960845-4

7 January 2021

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960845-4

7 January 2021

Minimal clinically important difference--exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960845-4

7 January 2021

Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960845-4

7 January 2021

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960845-4

7 January 2021

Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960845-4

7 January 2021

10.1016/S0140-6736(08)60845-4

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017